Drug Profile


Alternative Names: Alfetim Retard; Alfoten; Alfuzosin hydrochloride; Benestan; Dilotex; Mittoval; SL 77499; SL 7749910; Urion; Uroxatral; Uroxatrol; Xatral; Xatral OD; Xatral Retard; Xatral SR; Xatral XL

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi; sanofi-aventis
  • Class Quinazolines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Benign prostatic hyperplasia; Urination disorders
  • Discontinued Bladder dysfunction

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 04 Apr 2013 Alfuzosin licensed to Covis Pharma for commercialization in USA
  • 30 Jan 2013 NovaMed Pharmaceuticals renews its marketing license for alfuzosin in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top